Physician profile
Bruce Wayne Bennett
NPI 1225007818
$7,728.80
in general payments reported to CMS, 2019-2025
37 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $982 · 2022: $1,273 · 2023: $1,635 · 2024: $2,328 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,473.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,167.77 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,056.68 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $1,039.05 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $827.80 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $583.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $560.29 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $450.58 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $287.45 | 2021-2025 | |
| Abbott Laboratories | $262.31 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $147.12 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $144.03 | 2021-2025 | Evenity, Prolia, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $116.32 | 2021-2024 | Trintellix |
| Currax Pharmaceuticals LLC | $104.73 | 2021-2024 | Contrave, Nexlizet, Nexletol |
| Merck Sharp & Dohme LLC | $104.66 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Dynavax Technologies Corporation | $102.23 | 2022-2025 | Heplisav-B |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.